Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776647 | 0.78 | ADRA1D (0.53) | KCNH2CCR2HTR2A | |
| SCHEMBL13624817 | 0.69 | HRH1 (0.58) | HRH3KCNH2HRH1 | |
| SCHEMBL993093 | 0.68 | HTR2B (0.55) | KCNH2HRH1 | |
| SCHEMBL28370891 | 0.68 | CACNA1G (0.48) | HRH3HRH1CHRM3CACNA1GHTR2A | |
| SCHEMBL18884525 | 0.67 | HRH1 (0.68) | KCNH2HRH1 | |
| Oxalic Acid SCHEMBL9030775 | 0.67 | SLC6A4 (0.60) | HTR2A | |
| SCHEMBL14916479 | 0.66 | KCNH2 (0.51) | KCNH2HRH1 | |
| SCHEMBL6786077 | 0.66 | HRH2 (0.63) | HTR2A | |
| SCHEMBL4653613 | 0.66 | HRH1 (0.63) | HRH3JAK2JAK1JAK3KCNH2 | |
| SCHEMBL6782829 | 0.66 | HRH2 (0.46) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| EP-1497292-B1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-06-14 | — | — | EP | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
| EP-1497292-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003082867-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HTR1F 244/4885HRH3 4/4885HSD11B1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.